Biohaven 8-K (7.01, 9.01): Regulation FD disclosure

Biohaven said the FDA accepted its Vyglxia (troriluzole) resubmission for spinocerebellar ataxia review, considered it a complete response to its November 2025 action letter, set a first-quarter 2027 goal date, and plans an advisory committee meeting.